Building an in vivo model of Tau aggregation in Saccharomyces cerevisae by Andrerson, Jessica
Rhode Island College
Digital Commons @ RIC
Honors Projects Overview Honors Projects
4-2019
Building an in vivo model of Tau aggregation in
Saccharomyces cerevisae
Jessica Andrerson
janderson0006@gmail.com
Follow this and additional works at: https://digitalcommons.ric.edu/honors_projects
Part of the Biology Commons
This Honors is brought to you for free and open access by the Honors Projects at Digital Commons @ RIC. It has been accepted for inclusion in
Honors Projects Overview by an authorized administrator of Digital Commons @ RIC. For more information, please contact
digitalcommons@ric.edu.
Recommended Citation
Andrerson, Jessica, "Building an in vivo model of Tau aggregation in Saccharomyces cerevisae" (2019). Honors Projects Overview. 151.
https://digitalcommons.ric.edu/honors_projects/151
Building an in vivo model of Tau aggregation in Saccharomyces  
     cerevisiae 
   An undergraduate project presented 
    By Jessica Anderson 
        To the Biology Department 
    Faculty advisor: William Holmes, Ph.D. 
 1
BUILDING AN IN VIVO MODEL OF TAU AGGREGATION IN  
  SACCHAROMYCES CEREVISIAE 
    By Jessica Anderson 
A Project Submitted in Partial Fulfillment  
of the Requirements for 
Biology Departmental Honors 
in the Department of Biology 
The School of Arts and Sciences 
Rhode Island College 
April 2019 
Approved: 
________________________________                                                ______________ 
Project Advisor        Date 
________________________________          _______________ 
Honors Committee        Date  
________________________________          ________________ 
Department Chair        Date 
 2
      ABSTRACT 
Protein aggregates, which can result in cellular toxicity, are found in the brains of people 
afflicted with neurodegenerative diseases. One of the proteins found to aggregate is 
Tau, a protein that stabilizes microtubules in neuronal cells.  Based on its amino acid 
sequence, Tau is likely to be N-terminally acetylated by the complex NatA, which is 
responsible for the acetylation of a majority of proteins with this post-translational 
modification. Mutations in the NatA complex result in a variety of pleiotropic detrimental 
phenotypes, showing that acetylation is a crucial modification for many proteins. Without 
the presence of NatA – and therefore without acetylation – Tau may be more prone to 
aggregation and toxicity.  By expressing Tau in yeast strains with and without the 
presence of NatA, the possible effects of acetylation or lack thereof can be determined 
by examining protein expression and aggregation within the cells by SDS-PAGE and 
SDD-AGE.  Initial results indicate that Tau aggregates within these yeast cells although 
the nature and effect of the aggregates is still being determined.  This project has 
allowed for the creation of a system by which Tau aggregates can be examined in vivo.   
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Neurodegenerative Diseases 
 Neurodegenerative diseases are disorders which affect the vertebrate nervous system; 
they have been known to cause cognitive, behavioral, and motor function which progresses to 
eventual incapacitation1.  Many symptoms of neurodegenerative diseases (ND) overlap with 
psychiatric symptoms, particularly in the earlier phases of ND; this can lead to problems with 
misdiagnoses and ineffectual treatments2.  Proper diagnosis and treatment of ND is critical, 
especially as the numbers of people living with ND increase; it is expected that by 2050 there 
will be 18.5 million people living with ND2. It is therefore crucial to further investigate the 
underlying mechanisms that are responsible for disease onset and progression in the hopes of 
finding potential therapies and targets.   
 Neurodegeneration occurs in many forms, and although symptoms often overlap, there 
are many distinct disorders.  The most well-known neurodegenerative disorder is Alzheimer’s 
disease, although that only accounts for about 50-70% of dementia cases; the remaining cases 
of dementia are generally attributed to vascular dementia, frontotemporal lobar degeneration, 
corticobasal degeneration, progressive supranuclear palsy, and dementia with Lewy bodies3.  In 
addition, there are other neurodegenerative disorders that are not typically associated with 
dementia but rather with other symptoms, such as progressive non-fluent aphasia, amyotrophic 
lateral sclerosis, Huntington disease, and Parkinson’s disease2,4,5.  Certain disorders, such as 
corticobasal degeneration and progressive supranuclear palsy, can result in early motor 
problems, while others such as Alzheimer’s disease and some subtypes of frontotemporal lobar 
degeneration present only with personality and behavioral changes at the onset3.  As previously 
mentioned, this can frequently result in misdiagnoses, especially in younger patients with early-
onset conditions2,3.   
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 In many cases of neurodegeneration, misfolded proteins aggregate within the central 
nervous system and spread to new regions, increasing clinical symptoms as the damage 
spreads1.  Synapses between neurons may falter, and communication between neural 
pathways is affected1.  The different protein aggregates may be localized to certain regions of 
the brain, which may account for variation in symptoms between disorders1.  Multiple proteins 
have been linked to aggregation correlating with neurodegenerative disease, including β-
amyloid, TDP-43, α-synuclein, and tau. 
 Many disorders can be categorized as synucleinopathies or tauopathies5.  These 
characterizations are based off of the accumulation of α-synuclein or Tau aggregates in the 
nervous system, respectively, although co-localization of these proteins has been noted6. α-
synuclein is a 140-amino acid protein typically found in the axon terminals of neurons; it plays a 
role in synaptic function6,7.  The structure can be divided into three main regions: the N-terminal 
region, the hydrophobic region, which likely forms a beta sheet, and the acidic C-terminal 
region8.  α-synuclein has been found localized in the nucleus and cytosol as well as associated 
with the membrane9. Synucleinopathies, which can be thought of as a form of protein-misfolding 
disorders, typically contain α-synuclein in intracellular inclusions known as Lewy bodies7,9. 
Lewy bodies are characteristic in Parkinson’s disease, one of the most well-known 
synucleinopathies, as well as dementia with Lewy bodies, the second most common form of 
dementia7.  Lewy bodies can be found in many regions of the central nervous system, including 
the substantia nigra, locus ceruleus, nucleus basalis, hypothalamus, cerebral cortex, and cranial 
nerve motor nuclei11.   
 α-synuclein is encoded by the gene SNCA, and mutations within this gene have been 
linked with Parkinson’s disease, likely due to amino acid substitutions or conformational 
changes within α-synuclein resulting from the mutation11.  These gene mutations are not 
common and only account for about 1% of cases, but it is also possible that variants within this 
gene increase the risk of Parkinson’s even if they do not directly cause it11.  SNCA gene 
triplication and duplication has also been seen in cases of familial Parkinson’s; it has been 
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suggested that overexpression of the gene may be a factor in these patients11.   The potential 
for toxicity due to overexpression was shown in a yeast model as well; increasing the levels of 
α-synuclein twofold resulted in cytoplasmic inclusions and cell death11. It has also been 
suggested that different variants of the SNCA promoter may be associated with increased 
susceptibility to Parkinson’s11.  
Microtubule-Associated Protein Tau 
 Like α-synuclein, Tau is found in neuronal cells; it is a microtubule-associated protein 
which promotes microtubule polymerization and stability of polymerized microtubules12.  Six 
different forms of Tau exist in the adult human brain, ranging from 352 to 441 amino acids and 
produced via alternative splicing12.  The isoforms differ based on the presence or absence of 
29- or 58-amino acid sequences (N) near the N-terminus of the protein, and whether or not they 
have three or four tandem repeats (R) near the C-terminus12.  The full-length form of the protein 
is 2N/4R, but 0N/3R, 0N/4R, 1N/3R, 1N/4R, and 2N/3R are all expressed within the central 
nervous system in adults as well, although only the shortest 3R isoform of Tau is seen in fetal 
neurons12,13.  4R Tau has been shown to promote microtubule assembly around three times 
more than 3R Tau14.  In addition, granule cells and pyramidal cells within the human 
hippocampus have differing amounts of 3R and 4R Tau expression; differing degrees of 
microtubule polymerization and assembly may be unique within varying cell types, suggesting a 
reason for the differing isoforms14. 
  It has been previously suggested that some mutations resulting in frontotemporal 
dementia with Parkinsonism cause increased levels of 4R Tau compared with 3R Tau13.  Both 
3R and 4R Tau are capable of promoting microtubule polymerization; however, 4R Tau is 
capable of significantly stabilizing microtubules to a greater extent, suppressing shortening rates 
and reducing the length shortened overall13.  An increase in the levels of 4R Tau may potentially 
shift microtubule dynamics within the cell; a specific ratio of 4R to 3R may be needed in order to 
keep the microtubule dynamics within the narrow range necessary for functionality and prevent 
polymerization from occurring too quickly or slowly13.  Changes in these microtubule dynamics 
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within the cell may affect the cell’s capability to function.  Proper microtubule function is 
necessary for maintenance of cellular morphology and intracellular transport, both of which are 
crucial for neuronal cell health13. 
 In addition, mutations in the Tau protein can reduce its binding affinity for microtubules; 
G272V, P301L, V336M, and R401W mutants of Tau all showed reduced affinity for microtubule 
binding and reduced capability to facilitate microtubule polymerization15.  Impairing the proper 
function of Tau, even if the ratio of 4R to 3R remains the same, could also negatively affect the 
neuronal cells.   
 The hallmark of neurodegenerative diseases classified as tauopathies is the formation of 
Tau aggregates known as neurofibrillary tangles16.   In many cases, the Tau found in these 
aggregates is hyperphosphorylated16.   In normal adult neuronal cells, the phosphorylation of 
Tau is highly regulated by a variety of protein kinases and phosphatases16.  The phosphorylation 
of Tau plays a role in Tau-microtubule interactions and is suggested to serve as a negative 
regulator, decreasing the ability of Tau to bind to the microtubule16,17.  In addition, 
phosphorylation may affect the ability of Tau to bind to regulatory proteins16. The Tau found in 
fetal neurons is also hyperphosphorylated15,16. It is possible that in tauopathies, neuronal cells 
respond to some stressor by attempting to return to this initial proliferative phase, at least 
partially16.  
 Hyperphosphorylation is strongly implicated in Tau aggregation; one theory suggests 
that Tau aggregates via its microtubule-binding repeats, but the basic regions near these 
repeats, and the acidic C-region segment, inhibit Tau-Tau interaction18.  Phosphorylation of 
these regions neutralize these domains and allow interaction18.  Aggregation of Tau proceeds by 
monomeric Tau proteins associating with each other and forming dimers; a conformational 
change then results in larger oligomers19.  Multiple studies suggest that Tau oligomers may be 
more cytotoxic than larger aggregates, which appear as filaments in which a portion of each Tau 
protein adopts a beta-sheet conformation; the beta-sheets stack in parallel19,20.  In the earlier 
stages of aggregation, Tau oligomers are not ubiquitinated, but ubiquitination - a process which 
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allows for degradation of potentially toxic protein species - occurs during the transition from 
oligomers to filamentous aggregates; it is possible that an abundance of hyperphosphorylated 
Tau exceeds the proteasome’s capacity, and the formation of aggregates occurs as a way to 
shift the Tau into a more stable form19.  In addition, it has been theorized that certain post-
translationally modified forms of Tau - such as hyperphosphorylated Tau - are directly toxic even 
before their formation into aggregates, and the formation of aggregates is an attempt to 
sequester cytotoxic species of protein20. 
 In Alzheimer’s disease patients, the Tau present in neurofibrillary tangles is often 
truncated at the C-terminus, suggesting another post-translational modification that may be 
relevant to propensity to aggregation, at least in this specific disease21.  This truncation may be 
linked to exposure to amyloid precursor protein (APP, cleaved to amyloid-beta, Aβ), which 
suggests a potential link between their pathologies; unlike frontotemporal dementia with 
Parkinsonism, in which only Tau aggregates are present, Alzheimer’s disease includes both 
neurofibrillary tangles of Tau protein and extracellular amyloid plaques composed of Aβ21. 
Although previously thought of as independent pathologies, amyloid plaques and neurofibrillary 
tangles have been linked by recent studies showing that exposure to Aβ increases 
neurofibrillary tangles in a murine model21.  As it has been also suggested that amyloid plaques 
occur prior to Tau pathology, it is possible that the presence of Aβ plaques result in changes 
within the cell that alter the modification state and conformation of Tau, leading to aggregation22. 
This also implies that Aβ aggregation may be the trigger for Alzheimer’s disease, while Tau 
aggregation may occur as a downstream effect22.    
 It is also possible that interactions between α-synuclein and Tau may play a role in the 
formation of aggregates.  Co-occurrence of α-synuclein and Tau inclusions has been previously 
noted in human ND patients23.  Normal α-synuclein is capable of self-polymerization, while this 
is less likely to occur with Tau; α-synuclein can potentially act as a cofactor to initiate Tau 
fibrillization23.  Tau fibrillization in the presence of α-synuclein likely results from polymers of α-
synuclein that act as chaperones to produce a conformational change23.  In addition, rates of α-
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synuclein polymerization were shown to increase significantly in the presence of Tau, 
suggesting that Tau is capable of promoting α-synuclein fibrillization as well23.   
 Mechanisms already correlated with Tau aggregation include the previously-discussed 
post-translational modifications (PTMs): phosphorylation and truncation.  As any modification to 
a protein has the capability to affect its structure - and therefore its function - it is reasonable to 
assume that other modifications may also play a role in the propensity of Tau to aggregate 
within the cells.  One such modification, which has not been widely studied in this regard, is N-
terminal acetylation.   
N-Terminal Acetylation 
 Discovered over fifty years ago, N-terminal acetylation - the addition of an acetyl group 
to the N-terminus of a protein, thus changing the positive charge present on the N-terminus to a 
neutral charge - is one of the most common protein modifications in eukaryotic organisms, 
occurring in 85% of proteins in humans and 50% of proteins in yeast24.  The difference in these 
numbers suggests that acetylation patterns differ between species although the fundamental 
process remains the same, and indeed, this was shown to be true.  For instance, about half of 
human proteins with methionine-lysine termini are acetylated, but yeast proteins with this 
terminus are not acetylated25.   
 N-terminal acetylation is performed by one of six different N-terminal acetyltransferase 
(NAT) complexes - NatA through NatF - and the sequence of amino acids present in the 
protein’s N-terminus determines which NAT is responsible for acetylation of that protein24.  For a 
majority of proteins, it is only the first and second amino acid of the sequence that are 
responsible for affecting acetylation25.  Serine and alanine termini are most likely to be 
acetylated; methionine, glycine, and threonine are the next most likely, and 95% of acetylated 
proteins have one of these amino acids at their end terminus26.   
 NatA is the most active NAT complex, responsible for acetylating a majority of proteins - 
specifically those with Ser-, Ala-, Thr-, Gly-, Cys-, and Val- termini exposed by cleavage of the 
initial methionine25.  In contrast, NatB and NatC acetylate proteins with initial methionine 
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residues; NatB acetylates proteins with methionine followed by asparagine, aspartate, or 
glutamate while NatC acetylates those with methionine followed by isoleucine, leucine, 
phenylalanine, or tryptophan27.  NatD is specialized for acetylating the N-terminus of histone 
proteins, and NatE acetylates proteins that have leucine at position 2 and proline at position 429. 
NatF is responsible for acetylating proteins with initial methionine residues, specifically those 
followed by lysine, valine, alanine, or a second methionine28.   
 Given that cleavage of the initial methionine residue is a common post-translational 
modification in eukaryotic proteins, it follows that the NAT complex - NatA - responsible for 
acetylating proteins with this cleaved methionine is therefore responsible for acetylating the 
most protein.  NatA is composed of three subunits; in yeast, the main subunits are Nat1 and 
Ard124.  Ard1 is the catalytic subunit, while Nat1 is responsible for anchoring Ard1 to the 
ribosome, allowing co-translational modification25.  Both of these subunits are required for 
proper function of NatA, and the over-expression of both genes is necessary for overproduction 
of the NatA complex29.    Over-expression of only one subunit does not result in any significant 
increase in acetyltransferase activity, but when both are over-expressed, activity can increase 
up to 20-fold30.  In the same way, null mutants of Nat1, null mutants of Ard1, and double null 
mutants (Nat1/Ard1) in Saccharomyces cerevisiae all show very similar phenotypes, 
showcasing how both subunits are necessary for the proper function of the final protein30.   
 Since NAT complexes are responsible for acetylating proteins with a variety of functions, 
lacking one or more NAT complexes leads to defects in a variety of cellular processes and 
pathways which can be completely unrelated to one another30. In Saccharomyces cerevisiae, 
loss of N-terminal acetylation, caused by knockout of Nat1 and/or Ard1, results in several 
phenotypes including slow growth, inability to sporulate, and failure to enter G0 when 
necessary30.  Decreased mating, increased sensitivity to heat shock, and increased sensitivity to 
sodium chloride were also observed in mutant Saccharomyces cerevisiae with reduced N-
terminal acetylation28. Despite these defects, these strains remain viable, suggesting that N-
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terminal acetylation, although clearly important to the function of many proteins and the overall 
health of the cell, may not be completely necessary in all normally-acetylated proteins29.   
 In humans, however, disturbances to N-terminal acetylation are more prominent and 
more likely to result in lethality.  Ogden syndrome, an X-linked disorder, correlates to a mutation 
in the gene which encodes the catalytic subunit of the NatA complex31.  Symptoms include 
cranial abnormalities,    hypotonia, and cardiac problems, which eventually lead to death during 
infancy32.  Deregulation of NatA expression is also linked to the development of tumors32.  The 
human homolog of the Saccharomyces cerevisiae Nat1 unit, NATH, is found over-expressed in 
papillary thyroid carcinomas and is found in dividing tissues, suggesting that it might play a role 
in a cell’s ability to proliferate33.  Increased protein synthesis would be necessary in rapidly-
growing tumor cells, which would then result in the acetylation of more proteins overall.   
 The severity of effects in humans is likely due to the increased amount of proteins that 
are N-terminally acetylated in humans as opposed to Saccharomyces cerevisiae, as well as the  
increased complexity of the processes involved in a multicellular organism like Homo sapiens 
compared with a single-celled organism such as Saccharomyces cerevisiae.   
 The higher amount of proteins acetylated in humans rather than yeast could partially be 
due to a larger amount of NatB substrates; 19% of acetylated human proteins are acetylated by 
NatB, while only 9.5% of acetylated yeast proteins utilize NatB25.  In addition, a larger amount of 
amino acid sequences in humans can result in N-terminal acetylation - for instance, human 
proteins with the N-terminal sequence Met-Lys are acetylated while yeast-proteins with this N-
terminus are not25.   The increase in acetylation in multicellular eukaryotes such as humans is 
also likely due to the presence of NatF, which is not present in the single-celled eukaryotes such 
as S. cerevisiae28.  Divergence of both the NAT complexes themselves and their human protein 
targets could be responsible for the increased percentage of N-terminally acetylated proteins in 
humans25.   
 Although it is clear that the pleiotropic phenotypes seen with a lack of acetylation is likely 
caused by the wide variety of proteins which receive this modification, and disruption to this 
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modification results in the disruption of various other cellular pathways, it is not currently known 
what the true function of acetylation is.   It is apparently an irreversible process34.    N-terminal 
acetylation occurs when the nascent polypeptide chain is ~50 amino acids long, and can be 
considered a co-translational modification24.  As eukaryotic proteins fold co-translationally, it is 
reasonable to assume that N-terminal acetylation may play a role in protein folding as well24.   
 One study shows evidence that N-terminal acetylation can be responsible for the 
creation of degradation signals in proteins with this modification34.  Initially this seems 
impossible, since so many proteins, especially in higher eukaryotes, are acetylated, and many 
of them last a reasonable length of time before being degraded.  However, other processes 
could also play a role.  N-terminal acetylation may form degradation signals, but if the protein 
associates with chaperone proteins, forms a complex, or folds in a way that blocks the N-
terminus from associating with ubiquitin ligase or any other enzymes responsible for 
degradation, it may block the degradation signal from being recognized34.  On the other hand, if 
the protein is slow to properly fold or form a complex, the N-terminal degradation signal may 
remain open to the cellular environment and become recognized by ubiquitin ligase or others, 
resulting in quicker degradation; this suggests that N-terminal acetylation may potentially play a 
role in regulation and quality control34. 
 As expected from this potential role as a degradation signal, N-terminal acetylation does 
not protect against degradation by the proteasome35.  It is possible that protease resistance, 
folding, and thermal stability may be impaired in proteins without acetylation, but there is little 
evidence for these direct effects35.  It was shown in alpha-synuclein that N-terminal acetylation 
increases stabilization and helical propensity as well as decreasing rates of aggregation, likely 
due to secondary structure changes that resulted from the change from an N-terminal positive 
charge in the non-acetylated form to a neutral charge36.    Acetylation increases helicity in 
proteins, and this effect on the protein’s structure will cause varying effects depending on the 
particular protein and its function37.   
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 It has also been shown that N-terminal acetylation is far more common in cytosolic 
proteins - those that remain in the cytoplasm - than those which are sent to the endoplasmic 
reticulum for secretion out of the cell27.  Acetylation appears to inhibit protein targeting to the 
ER; most secretory proteins are unmodified, and the presence of acetylation decreases the 
chances of a protein being translocated and secreted out of the cell27.  It is possible, therefore, 
that the presence of acetylation is a marker that results in a protein staying within the cytoplasm 
instead of being moved to the ER27.   
 It has also been shown that lack of acetylation can be beneficial for certain proteins; in 
human hemoglobin, for instance, the acetylated form results in a reduced affinity of hemoglobin 
to oxygen38.   It has also been suggested that some proteins are only acetylated because their 
amino acid sequences are favorable to the NAT complex, and the protein does not actually 
require acetylation for its proper function38.  This could occur because evolution results in 
certain sequences being conserved for other reasons - for instance, a serine at position 2 of the 
amino acid sequence promotes phosphorylation and initial methionine cleavage as well as N-
terminal acetylation, but it is entirely possible that the protein only requires one of these for its 
function38.   
 Acetylation depends upon acetyl-CoA levels, since it is an essential cofactor in the 
process of N-terminal acetylation; this provides a clear link between cellular metabolism and 
acetylation39.  Inhibiting acetyl-CoA production in cells has resulted in lower levels of N-terminal  
acetylation as well as lower levels of apoptotic sensitivity39.  It is therefore clear that acetylation 
is a widespread process that affects many aspects of life within the cell, and its exact 
functionality likely cannot be narrowed down to just one factor.   
 In the same way, even the NAT complexes themselves may have multiple functions. 
New evidence suggests that NAT complexes are also capable of acting as 
propionyltransferases, transferring a propionyl group from propionyl-CoA to the N-terminus of a 
protein40.  Propionylation occurs at a lower rate than acetylation, which could be at least partially 
explained by the lower concentration of propionyl-CoA in cells compared to that of acetyl-CoA40. 
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It is a naturally occurring process; NAT complexes are capable of propionylating proteins both in 
vitro and in vivo40.  Currently, the modifications of acetylation and propionylation are not linked, 
but this shows how the NAT complexes may have a role in multiple cellular pathways.   
 Prevention of acetylation obviously occurs, as previously discussed, when one or more 
of the NAT complexes is not present or otherwise nonfunctional, but this is not the only way to 
block acetylation.  Presence of a proline at the first or second position of a polypeptide chain 
prevents acetylation; this is known as the (X)PX rule38.  Proteins with a proline at the second 
position remain non-acetylated even when the primary amino acid is serine or alanine, two 
amino acids which generally result in N-terminal acetylation by NatA38.  Knowing this (X)PX rule 
allows for manipulation of amino acid sequences to prevent a protein’s acetylation, allowing it to 
be studied for potential changes in stability or any other functions.  There is tentative 
experimental evidence for proline residues being acetylated in yeast, although this has not been 
proven; if it is true, it could potentially be another difference in acetylation between multicellular 
and unicellular eukaryotes38.   
Saccharomyces cerevisiae as a Model System 
 S. cerevisiae is a valuable tool as a model organism.  Although a unicellular eukaryote, it 
is still capable of carrying out many of the basic cellular processes - such as acetylation - which 
are important to life; unlike prokaryotes, it is capable of many post-translational modifications41. 
Practically speaking, yeast are straightforward to work with, inexpensive, and have a short 
generation time42.  Yeast are consistently used to produce foreign proteins, which allows this 
organism to be the model system for many different fields of research41.   
 Yeast are used as a model to study neurodegenerative diseases42.  Although these 
diseases themselves may only be present in some multicellular organisms, the processes which 
occur in affected organisms can also be observed in a unicellular system.  Studying 
tauopathies, for instance, is entirely capable in S. cerevisiae; expression of Tau in yeast does 
not result in a negative phenotype42.  This provides a perfect basis for studies of Tau; if the 
protein alone does not result in a notable stress response of any kind, experimental 
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manipulations can more easily be performed.  One such manipulation which has been 
previously studied is the co-expression of Tau and α-synuclein; as co-localization has been 
noted in clinical samples, the association continues to be investigated42.   
 α-synuclein itself has caused growth delays when expressed in S. cerevisiae; when it 
was co-expressed with Tau, the growth delays seen were comparable to that of when α-
synuclein was expressed alone, with no additive effect resulting from the inclusion of Tau42.  As 
previously stated, expression of Tau on its own did not result in arrested growth42.  The 
presence of α-synuclein affected solubility of Tau, resulting in a higher fraction of insoluble 
(aggregated) Tau protein than what was seen in cells with Tau alone42.  α-synuclein was also 
found to increase the levels of phosphorylated Tau42.  It has been previously suggested that α-
synuclein forms a complex of sorts with GSK3β (the kinase which mediates phosphorylation) 
and Tau which results in increased phosphorylation; this finding suggests that it is capable of 
forming a similar complex with a yeast orthologue of GSK3β42,43.  These results do show that 
Tau is phosphorylated and is capable of aggregating within S. cerevisiae although no negative 
phenotypes were directly associated with increased levels of Tau phosphorylation and 
aggregation; this result could potentially just be explained by the difference between yeast cells 
and human neurons42.   
 Tau phosphorylation or hyperphosphorylation is not only observed in the presence of α-
synuclein; human protein Tau expressed in yeast on its own, without any other foreign proteins, 
is capable of aggregating and being phosphorylated44.  In S. cerevisiae, this process is    
controlled by yeast kinases; two suggested to be particularly important are Mds1 and Pho85, 
which are the orthologues of the human kinases GSK3β and cdk5, respectively44.  Tau 
expressed in yeast strains lacking Pho85 were shown to have increased amounts of 
phosphorylation and aggregation, suggesting that Pho85 - and therefore possibly cdk5 in  
neuronal cells - acts as a negative regulator of these processes44.  Absence of Mds1, on the 
other hand, resulted in decreased amounts of hyperphosphorylated Tau44.  Both 3R and 4R 
isoforms of Tau were used in the study, and although both were phosphorylated, there was a 
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marked difference in that 3R was not seen to undergo extensive aggregation while 4R was44. 
Overall the finding that the 4R isoforms aggregate more readily than the 3R isoforms implies 
that the extra microtubule-binding domain may potentially be relevant in the formation of 
aggregates44.  That being said, binding of Tau to yeast microtubules has not been previously 
noted, suggesting that it may be the structure of this domain, rather than its function, which is 
particularly important in aggregate formation44.  Because Tau is not currently known to bind to S. 
cerevisiae microtubules, studies regarding microtubule binding must be done outside the cell; 
that being said, the Tau protein used in said studies can be expressed and purified from yeast 
cells, reducing the need to use the more expensive, complicated, and time-consuming 
mammalian cell cultures.  Tau-4R purified from yeast retains its ability to bind to microtubules 
and has been noted to do so in vitro45.   
 Phosphorylation was decreased in the absence of mds1, and ability to bind increased;  
likewise, phosphorylation increased in the absence of the negative regulator Pho85 and ability 
to bind to microtubules decreased45.  Hyperphosphorylated Tau isolated from neuronal cells of 
Alzheimer’s disease patients also was shown not to have normal interactions with microtubules, 
confirming this finding45.  A mutant isoform of Tau (P301L) was also used in this study, and it 
was shown to aggregate on the microtubules themselves45.  Mutations in the gene encoding for 
Tau can lead to a variety of mutant Tau forms, which may contribute to disease by being more 
prone to aggregation45.  The hyperphosphorylated form disturbed the overall structure and 
organization of the microtubules but did not appear to form large clusters on them; it was 
assumed that this form resulted in smaller aggregates45. 
 Another factor potentially affecting the behavior of Tau protein is oxidative stress, in 
which reactive oxygen species or free radicals are formed within the cell46.  It has been 
previously suggested that oxidative stress may play a role in tauopathies, playing a role in the 
formation of neurofibrillary tangles in conjunction with hyperphosphorylation46.  Treatment of 
yeast cells with ferrous sulfate resulted in increased levels of insoluble Tau in wild-type cells46. 
Both mutant Tau forms and the wild-type 2N-4R isoform consistently showed these increased 
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levels of aggregation; however, it was noted that the mutant forms showed significantly higher 
levels of aggregation than that of the the 2N-4R isoform, suggesting that the mutants are more 
susceptible to aggregation induced via oxidative stress46.   This experiment was also performed 
on cells lacking the Pho85 kinase, although the effect was not as noteworthy as that of the wild-
type cells46.  Analysis by Western blot suggested that Tau - or at least the 2N-4R isoform - could 
actually be dephosphorylated under oxidative stress conditions46.  Overall, this suggests that 
oxidative stress acts in parallel to phosphorylation to cause aggregation46.  Iron ions have also 
been found in Lewy bodies, and addition of iron ions to yeast cells expressing alpha-synuclein 
showed increased aggregation, suggesting that oxidative stress may play a role in many 
different forms of neurodegenerative disease, and this can also be easily replicated in this yeast 
model47.  
 It is clear, therefore, that multiple factors likely correlate with increased aggregation. 
Phosphorylation has been previously linked with acetylation; however, the effects of other post-
translational modifications have not been extensively examined.  N-terminal acetylation is the 
most common protein modification24, yet it has not been considered as a potential factor which 
could affect aggregation.  S. cerevisiae is capable of N-terminally acetylating proteins, and has 
previously been characterized as a useful model system for protein expression in vivo41.  This 
project has involved expressing Tau in S. cerevisiae with the goal of creating a system with 
which to examine the effects of acetylation on Tau in vivo.   
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    MATERIALS AND METHODS 
Yeast growth 
Unless otherwise stated, all cultures were grown in YPD media at 30°C, and a roller drum or 
shaking platform was used to allow for aeration.  Heat shock treatments were performed by 
growing the yeast at 37°C for at least four hours.   
Yeast strains 
74D-694 (psi- WT) cells were used as a parent strain and served as the wild-type control for all 
experiments, as well as providing the wild-type background for integrant strains.  74D-694 cells 
with the the nat3 subunit of NatB knocked out served as the parent strain for all ∆NatB 
integrants mentioned.  64D-694 cells with the mak3 subunit of NatC knocked out served as the 
parent strain for all ∆NatC integrants mentioned.  ∆NatA strains had both the Ard1 and Nat1 
subunits of ∆NatA knocked out.   
Plasmids 
pYX212-Tau (2N4R) with +URA selection marker 
pRS304-GPD (Tau-GFP) with +TRP selection marker 
pRS304-GPD (Tau-A2P) with +TRP selection marker 
pRS304-GPD (Tau-A2P-GFP) with +TRP selection marker 
Integration of plasmids into yeast genome 
Each plasmid (Tau, Tau-A2P, Tau-GFP, Tau A2P-GFP) was linearized by restriction digest with 
the enzyme Bsu36I prior to integration. 10mL of cells were spun down and washed before 
resuspension in 50 uL  of 100 mM LiAc prior to a 15-minute 30°C incubation period.  The cell 
suspension was then added to the solution of linearized plasmid and 300 uL of PEG-LiAc was 
added prior to another incubation period of 30 minutes at 30°C.  Heat shock at 42°C for 20 
minutes then followed.  Cells were pelleted and resuspended in sterile water before plating on 
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selective media (SD-URA for Tau integrants, SD-TRP for Tau-A2P, Tau-GFP, or Tau A2P-GFP 
integrants).   
SDS-PAGE 
2.5 ODs of yeast cells were lysed via NaOH lysis and resulting lysates were resuspended in 50 
uL of SDS sample buffer (2.25 mM BME, 1.3 mM SDS, 10 mM glycerol, 0.07% bromophenol 
blue, 12% 1 M Tris-HCl 6.8).  8% polyacrylamide gels allowed for resolving of proteins, which 
were then transferred onto a PVDF membrane and visualized via standard Western blot 
procedure using anti-Tau and anti-GPD antibodies.   
SDD-AGE 
40 ODs of cells were spun down and washed, keeping everything on ice.  Standard glass bead 
lysis was used to lyse the cells.  Samples were then added to SDD-AGE sample buffer (24% 
1M Tris-HCl 6.8, 15% glycerol, 3 mM SDS, 3 mM bromophenol blue) and incubated at 30°C for 
5 minutes.  Lysates were loaded onto a 1.25% agarose gel containing 0.0002% SDS in a Tris-
glycine buffer.  1x LRB was used as a running buffer. Gels were resolved for roughly 40 minutes 
at 160V and transferred onto a PVDF membrane at 20V for 3 hours.  Visualization was done 
using standard Western blot procedure with anti-Tau antibody.   
Microscopy 
A wet mount of 10 uL of exponentially growing culture was prepared, and excess light exposure 
on the slide was minimized by keeping the slide in an enclosed container until visualization. 
Slides were visualized via fluorescence microscopy at 40x magnification.   
Oxidative stress treatment 
100 mL cultures were treated with 1M FeSO4 for two hours before centrifugation and lysis in 
order to cause oxidative stress. 
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      RESULTS 
Expression of the Microtubule-Associated Protein Tau in Saccharomyces cerevisiae 
 As Tau is a protein found in mammalian neurons, our model system of S. cerevisiae are 
not capable of endogenously producing this protein of interest1.  Standard LiAc/PEG yeast 
transformation protocol is useful but has to be consistently repeated since future generations of 
cells do not retain the plasmid.  As a result, the transformation protocol was adapted to include 
the linearization of the Tau plasmid via restriction enzyme (Fig. 1) to allow for insertion directly 
into the yeast genome to ensure that the production of Tau remained constant from one 
generation to the next.   
 Although S. cerevisiae do not endogenously produce Tau, they are capable of post-
translational modifications such as N-terminal acetylation, which is performed by one of several 
N-acetyltransferase (NAT) complexes2.  Based on its amino acid sequence, Tau is predicted to 
be acetylated by NatA.  In order to determine the effect of acetylation or lack thereof, four 
strains were chosen for integration with the Tau plasmid: wild-type, ∆NatA, ∆NatB, and ∆NatC. 
The Tau plasmid also contained a marker for growth on selective media (in this case, +URA) 
which ensured that only cells which successfully took up the plasmid would grow on SD-URA 
plates.  As each integration resulted in multiple colonies, several colonies were selected for 
screening in order to determine the most efficient production of Tau in each strain.  The colonies 
were restruck on a selective plate and lysed in order to examine expression of Tau, which was 
visualized via Western blot (Figure 2A, 2B).  These Western blots were used to determine the 
best integrant colony which was done by examining the blot for the most effective protein 
expression (that is, the darkest band), and this process was repeated for all four strains.   
 Following this process, the selected integrant colonies were frozen down as new strains 
of yeast for use in future experiments.  Expression of Tau was again confirmed by Western blot 
of the four new strains and their parent strains, which lack Tau (Figure 3).  In order to examine 
whether any growth differences were qualitatively observed, a spot plate of the parent strains 
and the Tau strains was performed (Figure 4A).  The presence of Tau did not appear to inhibit 
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growth; conversely, in some cases, the strains with Tau seemed to have increased growth 
compared with the wild-type or ∆Nat knockout parent strain.   
Production of Tau-A2P Strain 
 Although the ∆NatA+Tau strain created is assumed to have unacetylated Tau, it is also 
true that this strain has a large amount of other proteins which are typically acetylated.  Yeast 
strains lacking NAT complexes typically show phenotypic deficits in temperature resistance, 
growth, mating, and other variables3,4.  Because of this, it could potentially be difficult to 
determine whether any differences seen between the WT+Tau and ∆NatA+Tau strain are solely 
due to the acetylation status of Tau, as opposed to a downstream effect based on the complete 
loss of the NatA complex.  To account for this, a version of Tau containing a substitution at the 
second position (alanine to proline) was also utilized.  A proline at the second position blocks 
acetylation5, so by integrating this version of the Tau plasmid into wild-type yeast, we could have 
unacetylated Tau in a completely healthy background.  The same protocol for integration into the 
yeast genome was followed; the selective marker here was +TRP so the successful integrants 
would grow on SD-TRP media.  Integrant colonies were screened by selection of the colony 
with the best protein expression, analyzed via Western blot (Figure 5A).  The Tau-A2P plasmid 
was also integrated into ∆NatA cells (Figure 5B).  Expression of Tau was again confirmed for all 
of the Tau-producing strains via Western blot (Figure 5C).  Growth differences were examined 
via spot test (Figure 4B).  There did not appear to be any differences between the growth of 
strains producing Tau and the wild-type strain (Figure 4B). 
Visualization of Tau Aggregation in S.cerevisiae by SDD-AGE 
 Although SDS-PAGE is a very useful tool for determining whether or not a protein is 
expressed, this method is not particularly conducive to examining aggregation; aggregates do 
not typically survive the denaturing conditions, and are also typically too large for the pores of a 
polyacrylamide gel.  In order to visualize Tau aggregates in S. cerevisiae, we utilized SDD-AGE 
(Semi-Denaturing Detergent Agarose Gel Electrophoresis) which has previously been utilized to 
examine other forms of aggregates. SDD-AGE has previously been used for visualization of 
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Sup35 prion aggregates in yeast, but has never before been used to visualize Tau aggregates. 
In order to determine whether or not this method would be sufficient for visualization of Tau 
aggregates, Sup35-HA prion aggregates were utilized as a control.  As seen in Figure 6, the 
Sup35-HA aggregates were higher on the gel than the Tau aggregates; this indicates the Tau 
aggregates are smaller than Sup35 aggregates, but a quantitative comparison is not possible 
due to the current lack of a proper standard or ladder for this method.    
 As this method requires a large OD of cells, we next wanted to determine whether or not 
it was feasible to use frozen pellets or if this method always had to be started from fresh pellets 
(Figure 7).  WT+Tau cells were flash-frozen via liquid nitrogen and placed in a -80°C cooler. 
Another sample of ∆NatC+Tau cells were placed in the freezer without flash-freezing.  As 
comparison, a fresh sample of WT+Tau cells was taken, and then all three samples were lysed 
and run on the gel.  The lanes of both frozen samples had no visible signal on the Western blot, 
suggesting that some aspect of the freeze-thaw cycle disrupts aggregation, and therefore 
freezing down pellets is not adaptable to this method.  In the future, it may be useful to 
determine whether or not the total proteome is disrupted by the freeze-thaw cycle, or whether 
this may be a Tau-specific effect. 
 Next, multiple strains of Tau-producing yeast were examined via this method to 
determine Tau aggregation between strains with and without acetylation (Figure 8, Figure 9). 
Although the strains of different aggregates are not identical, they are consistently similar in 
size.  Small differences may be noted, such as a slight shift up in Tau-A2P (Figure 9) but without 
a ladder there is no way to quantify this kind of minor shift.   
 In addition to directly examining the differences between strains, we were also aiming to 
examine the potential differences in aggregates when exposed to cellular stress.  In an attempt 
to examine this, a sample of WT+Tau yeast was treated for two hours with 1M FeSO4, which 
results in oxidative stress for the cells6.  This sample and a control sample of WT+Tau yeast 
which had not received the oxidative stress treatment were examined via SDD-AGE (Figure 10). 
A slight shift upward may be apparent in the 2-hr treatment lanes, but as before with the 
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different strains, small shifts are difficult to quantify or fully claim without a standard.  Future 
experiments will involve examining the different strains when under some form of cellular stress 
to see whether there is a noticeable difference between the aggregates of different strains when 
exposed to the same stressor.   
Examination of Cellular Stress by Microscopy 
 Microscopy is often used as a tool to visually examine differences between cells.  In 
particular, green fluorescent protein (GFP) can be a valuable tool for examining localization and 
therefore aggregation, since GFP is easily visible in cells with the aid of a fluorescent 
microscope.  In order to determine whether differences between localization and/or amount of 
GFP-tagged protein can be visualized using this method, strains containing GFP fused to heat 
shock protein 104 were examined. Two different strains - one [PSI+] and one [psi-] - were 
examined with and without the presence of a heat shock treatment in order to qualitatively 
determine if a difference was visible in the amount and localization of Hsp104-GFP (Figure 11). 
In both cases the heat shock treatment resulted in brighter patches of Hsp104-GFP, although it 
is important to note that this was qualitative and no quantification or cell-counting was 
performed to determine significance.   
 Following this determination, the psi- strain containing Hsp104-GFP was transformed 
with either the empty vector or the Tau plasmid and again examined under the microscope to 
examine whether or not the presence of Tau within the cells appeared to be a version of cellular 
stress analogous to heat shock which would result in increased levels of this chaperone protein 
(Figure 12).  Qualitatively, it did appear that for at least some of the cells, the presence of Tau 
was a stressor which increased in increased levels of chaperone proteins, which were seen as 
brighter green cells.   
Production and Examination of Strains Containing Tau-GFP 
 Since examining cellular stress by chaperone expression does not directly examine the 
effects of Tau aggregates, new strains were created which had a Tau-GFP construct.  Once 
again, the plasmid was linearized and integrated directly into the yeast genome, and several 
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integrant colonies were selected for screening from each strain (Figure 13A).  The Tau-GFP 
plasmid was integrated into wild-type, ∆NatA, and ∆NatC cells.  In addition, a construct 
containing A2P-Tau-GFP was also integrated into WT and ∆NatA yeast for the same purpose as 
the creation of the initial Tau-A2P strain; any differences seen could then be assumed to be the 
result of the acetylation status of Tau rather than downstream effects of lacking the NatA 
complex completely.  Expression of Tau for all of the GFP strains was again confirmed via 
Western blot (Figure 13B).  Growth differences were visualized via spot test (Figure 14). 
Expression of Tau-GFP was confirmed via fluorescence microscopy (Figure 15). 
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Figure 1: Schematic explaining the integration of genetic material into the 
Saccharomyces cerevisiae genome.  LiAc transformation of yeast cells was adapted to 
include the linearization of the plasmid of interest in order to insert into the chromosome.   
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 Figure 2: Examples of isolate screening Western blots. Following integration, colonies 
which successfully grew on selective media were isolated and restruck on a second plate.  Each 
of those colonies was then lysed, and the lysates ran on SDS-PAGE.  A: Expression of Tau in 
wild-type yeast integrated with the linearized Tau plasmid.  B: Expression of Tau in ∆NatA yeast 
integrated with the linearized Tau plasmid.    
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Figure 3: Initial Tau-producing strains and parent strains.  Tau expression visualized via 
Western blot with anti-Tau antibody and anti-GPD load control. 
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Figure 4: Spot test showing parent strains and mutant strains.  A: Parent strains and initial 
Tau-producing strains.  B: Strains containing Tau-A2P.  Spot tests generated by diluting a 
saturated overnight culture by a factor of 1:10 for each successive spot.   
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Figure 5: Expression of Tau-A2P.  A: Expression of Tau in integrant colonies of WT+Tau-A2P, 
compared to the previously-created WT+Tau strain, visualized via Western blot with anti-Tau 
antibody.  B: Expression of Tau in integrant colonies of ∆NatA+Tau-A2P, visualized via Western 
blot with anti-Tau antibody.  C. Western blot of Tau-producing strains with GPD load control. 
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Figure 6: SDD-AGE of Tau aggregates andSup35-HA prion aggregates.  Sup35-HA prion 
aggregates were run as a control, since Tau has never been visualized by this method 
previously.  Anti-Tau antibody was used as the primary, and anti-HA was added to the secondary 
antibody solution.   
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Figure 7: SDD-AGE of fresh and frozen pellets.  Visualized via Western blot using an anti-Tau 
antibody. 
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Figure 8: SDD-AGE comparing the Tau aggregates of three Tau-producing strains.  
Visualized via Western blot using an anti-Tau antibody. 
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Figure 9:  SDD-AGE showing WT Tau compared with ∆NatA, A2P, and ∆NatC.  Visualized 
via Western blot using an anti-Tau antibody. 
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Figure 10:  Effects of oxidative stress on WT+Tau yeast.  Effects of oxidative stress and/or 
heat stress will be examined in the different strains.  Visualized via Western blot, using an anti-
Tau antibody. 
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Figure 11: Qualitative microscopy of Hsp104-GFP cells. Microscopy, with the aid of GFP-
tagging proteins, can be another method to examine cellular stress.  Cells with GFP-tagged 
heat shock protein 104 (Hsp104) were heat shocked to qualitatively examine differences in GFP 
expression and determine whether this is an optimal method to potentially examine cell stress.   
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Figure 12:  Qualitative microscopy of psi- Hsp104-GFP cells either transformed with the 
Tau plasmid or an empty vector.   
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Figure 13: Tau expression of Tau-GFP strains.  A: Sample isolate Western blot showing the 
expression of Tau-GFP in the WT+Tau-GFP integrant colonies compared to WT+Tau.  B: 
Expression of Tau-GFP in the final strains, visualized via Western blot. 
 44
W
T+
Ta
u 
Is
ol
at
e 
1 
Is
ol
at
e 
2 
Is
ol
at
e 
3 
Is
ol
at
e 
4 
Is
ol
at
e 
5 
Is
ol
at
e 
6 
Is
ol
at
e 
7 
Is
ol
at
e 
8 
W
T 
W
T+
Ta
u 
W
T+
Ta
u-
G
FP
 
∆N
at
A
+T
au
-G
FP
 
∆N
at
C
+T
au
-G
FP
 
W
T+
Ta
u-
A
2P
-G
FP
 
∆N
at
A
+T
au
-A
2P
-
G
FP
   
  Tau 
B. 
  GPD
Figure 14:  Spot test of GFP strains.  Saturated overnight cultures were diluted 1:10 for each 
successive spot.   
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Figure 15:  Representative sample images of Tau-GFP strains under the microscope. 
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	 	 	 	 	 DISCUSSION

	 Although N-terminal acetylation is a very common post-translational modification, its 
effects on the protein Tau have not been properly examined.  The amino acid sequence of Tau 
suggests that it is a suitable candidate for acetylation by the NatA complex; an alanine residue 
exposed by methionine cleavage, as seen in Tau, is a common target for NatA1,2.  In addition, 
acetylation of Tau’s N-terminus has been observed in both Tau from Alzheimer’s patients and 
normal Tau2.  It is reasonable to predict that if this modification is indeed present, then it likely 
has some effect on the protein.  N-terminal acetylation changes the positive N-terminus to a 
neutral charge by the addition of an acetyl group3.  Any change in charge could potentially 
affect the propensity of a protein to interact with other molecules within the cell; it could also 
affect the way in which the protein folds. It is important to examine all factors which may play a 
role in Tau’s structure and function; changes in any of these pathways could contribute to 
aggregation and tauopathy.  Other modifications such has hyperphosphorylation have 
previously been correlated with increased aggregation; although these studies do not discuss 
acetylation directly, they do show how changes to the protein’s structure can affect stability 
and function.  

	 S. cerevisiae provide a useful model organism for protein expression; their eukaryotic 
structure provides at least a basal similarity to human cells4.  They endogenously contain the 
NAT complexes responsible for acetylation as well as the molecular machinery to perform other 
post-translational modifications4.   S. cerevisiae have been previously utilized as a model to 
study neurodegenerative disease, and expression of Tau in yeast is efficient and does not 
cause negative phenotypes5.  Based on amino acid sequence, Tau should be acetylated in 
wild-type yeast.  Expressing Tau in S. cerevisiae allows for experiments in vivo which can 
examine changes to acetylation status.  By examining the difference in results between the 
strain containing Tau-A2P and the strain which lacks NatA entirely, for instance, it can be 
determined whether the potential effects seen are due to the effect of Tau specifically lacking 
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acetylation or due to an overall reduction of acetylated proteins within the cell and disruption of 
other cellular pathways that may result in downstream effects on Tau. 

	 The formation of Tau aggregates is heavily implicated in neurodegenerative disease6.  
Any method which can characterize or examine Tau aggregates could provide insight into 
factors affecting aggregation as well as allow for characterization of these aggregates.  This 
project showcases the first occurrence of SDD-AGE being utilized to examine Tau aggregation.  
SDD-AGE has been previously utilized to examine other protein aggregates, such as Sup35 
prion aggregates from S. cerevisiae, but it has not been previously used as a method to 
examine Tau.  Our results show that this method is a viable option for visualizing Tau 
aggregates.  Although no notable differences have been seen in aggregate sizes between the 
strains, future work will attempt to examine the effect of different treatments and how the 
strains respond.  It could be possible that under normal conditions, unacetylated and 
acetylated Tau aggregate at similar rates, but with the addition of a further stressor, changes in 
aggregation dynamics may be visible.  Increased aggregation has been noted under various 
experimental conditions, including mutations in the Tau protein7, oxidative stress7, and the 
presence of α-synuclein5.  This suggests that aggregation is affected by multiple factors which 
may work in parallel with one another, and disease conditions may not be directly caused by 
any one on its own.  It is therefore crucial to examine the interplay of different conditions.  Heat 
and oxidative stress are typically utilized in yeast models to examine cell stress, and these will 
likely be the first conditions examined further.  Preliminary work was done with an oxidative 
stress treatment (Figure 10); these results are not fully conclusive but may indicate that 
oxidative stress does slightly increase aggregate size in WT+Tau yeast, suggesting that this 
treatment may be a viable method for affecting aggregation rate/amount.  Further directions 
will include utilizing some form of oxidative stress treatment like this on all of the different yeast 
strains as well as testing heat stress to determine whether that could also differentially affect 
aggregate size between strains.
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	 These differences in aggregate size will also be examined via microscopy.  Preliminary 
data suggests that fluorescence microscopy is a viable tool for examining localization of GFP-
tagged proteins in S. cerevisiae cells; although none of the data collected has been quantified, 
this again suggests that this method could be utilized in the future to examine differences 
between strains.  The same sort of conditions which will likely be examined via SDD-AGE - that 
is, heat stress and oxidative stress - will also be used to treat cells prior to microscopy in order 
to potentially visualize the differences in aggregation within the cells themselves.  Ideally, the 
results gained from microscopy and the results gained from SDD-AGE could together provide a 
more complete picture of Tau aggregation within the strains.  Fluorescence microscopy could 
also provide insight into localization of aggregates within cells, particularly if it differs among 
conditions.  

	 So far, this project has established that S. cerevisiae is a useful model for examining Tau 
aggregation.  Tau has been constitutively been expressed in multiple strains with and without 
acetylation, and although precise effects of acetylation have yet to be conclusively determined, 
it is safe to say that this system provides a valuable basis for further experiments regarding 
acetylation’s effects.  We have shown that Tau aggregates within yeast strains and these 
aggregates can be visualized by way of SDD-AGE, and GFP-tagged Tau aggregates can be 
visualized via fluorescence microscopy.  The results shown here have laid the groundwork, 
allowing for future experiments which aim to determine the effect of acetylation or lack thereof 
on aggregation of Tau.  As any modification to a protein can cause structural changes, which 
can therefore impact its interactions with other proteins, it is important to examine all of these 
modifications to Tau in the hopes of finding ways to potentially reduce aggregation.
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